特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959707

BLU 782:新薬の洞察と市場予測 (2030年)

BLU 782- Emerging Drug Insight and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
BLU 782:新薬の洞察と市場予測 (2030年)
出版日: 2020年09月08日
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

BLU 782は、Blueprint Medicinesが独自の科学的プラットフォームを使用して、進行性骨化性線維異形成症 (FOP) の根本原因である変異ALK2を選択的に標的とするように設計されました。第I相の治験では、健康な被験者への投薬が既に完了しており、BLU 782がすべての用量で忍容性が良好であることを示す予備データが得られました。 FDAはBLU 782に、まれな小児疾患指定、オーファンドラッグ指定、およびファストトラック指定を付与しています。

当レポートでは、進行性骨化性線維異形成症 (FOP) の治療薬であるBLU 782の市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2020~2030年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、資本取引の動き、今後の市場成長の可能性などを調査・考察しております。

目次

第1章 医薬品の概要

  • 製品の詳細情報
  • 作用機序
  • 用法・用量
  • 研究開発 (R&D) 活動
    • 臨床開発
    • 安全性・有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国 (7MM) の市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場参入企業

第6章 その他の新たな治療法

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 BLU 782, Description
  • Table 2 BLU 782, Clinical Trial Description
  • Table 3 BLU 782, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of BLU 782
  • Figure 2 Patent Details, BLU 782
  • Figure 3 BLU 782, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 BLU 782, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 BLU 782, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 BLU 782, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0058

"BLU 782- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Fibrodysplasia ossificans progressiva (FOP) in 7 Major Markets. A detailed picture of the BLU 782 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

BLU-782 was designed by Blueprint Medicines to selectively target mutant ALK2, the underlying cause of FOP, using Blueprint Medicines' proprietary scientific platform. Blueprint Medicines recently completed dosing in a Phase 1 clinical trial of BLU-782 in healthy volunteers and reported preliminary data at the American Society of Bone and Mineral Research Annual Meeting in September 2019, which showed that BLU-782 was well-tolerated at all doses tested. Previously reported preclinical data in a well-characterized, genetically accurate FOP model showed that BLU-782 prevented injury- and surgery-induced heterotopic ossification, reduced edema and restored healthy tissue response to muscle injury. The FDA has granted a rare pediatric disease designation, orphan drug designation and fast track designation to BLU-782.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around BLU 782.
  • The report contains forecasted sales for BLU 782 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Fibrodysplasia ossificans progressiva (FOP).
  • The report also features the SWOT analysis with analyst insights and key findings of BLU 782.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BLU 782 Analytical Perspective by DelveInsight

  • In-depth BLU 782 Market Assessment

This report provides a detailed market assessment of BLU 782 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • BLU 782 Clinical Assessment

The report provides the clinical trials information of BLU 782 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Fibrodysplasia ossificans progressiva (FOP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence BLU 782 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Fibrodysplasia ossificans progressiva (FOP) are giving market competition to BLU 782 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of BLU 782.
  • Our in-depth analysis of the forecasted sales data of BLU 782 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BLU 782.

Key Questions:

  • Which company is developing BLU 782 along with the phase of the clinical study?
  • What is the technology utilized in the development of BLU 782?
  • What is the product type, route of administration and mechanism of action of BLU 782?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BLU 782 development?
  • What are the key designations that have been granted to BLU 782?
  • What is the forecasted market scenario of BLU 782?
  • What is the history of BLU 782 and what is its future?
  • What is the forecasted sales of BLU 782 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to BLU 782?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.